0001193125-26-059883.txt : 20260219 0001193125-26-059883.hdr.sgml : 20260219 20260219190523 ACCESSION NUMBER: 0001193125-26-059883 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260217 FILED AS OF DATE: 20260219 DATE AS OF CHANGE: 20260219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bredt David CENTRAL INDEX KEY: 0002022087 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42121 FILM NUMBER: 26656098 MAIL ADDRESS: STREET 1: C/O RAPPORT THERAPEUTICS STREET 2: 1325 BOYLSTON ST., SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rapport Therapeutics, Inc. CENTRAL INDEX KEY: 0002012593 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 880724208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-321-8020 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2026-02-17 0002012593 Rapport Therapeutics, Inc. RAPP 0002022087 Bredt David RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100 BOSTON MA 02110 false true false false Chief Scientific Officer true Common Stock 2026-02-17 4 S false 900 28.0211 D 394675 D Common Stock 2026-02-17 4 S false 5400 28.9497 D 389275 D Common Stock 2026-02-17 4 S false 2200 29.5944 D 387075 D Common Stock 2026-02-19 4 M false 6000 1.8 A 393075 D Stock Options (Right to Buy) 1.8 2026-02-19 4 M false 6000 0 D 2033-12-05 Common Stock 6000 88080 D These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction. 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. /s/ Troy Ignelzi, Attorney-in-Fact 2026-02-19